2-Fluoro-6-methoxy-3-methylpyridine | 1227580-97-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Fluoro-6-methoxy-3-methylpyridine
• 英文别名: 2-fluoro-6-methoxy-3-methylpyridine
• CAS: 1227580-97-3
• 化学式: C₇H₈FNO
• 分子量: 141.14
• InChiKey: VKLMAJZETAJDPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• THERAPEUTIC AGENT FOR TAUOPATHIES
  申请人：Sumitomo Pharma Co., Ltd.

  公开号：EP4104861A1

  公开（公告）日：2022-12-21

  The present invention is to provide a medicament for treating and/or preventing tauopathy by activating the voltage-gated sodium channel (Nav). The present invention relates to a medicament for treating and/or preventing tauopathy, comprising a Nav activator as an active ingredient.

  本发明提供了一种通过激活电压门控钠通道（Nav）治疗和/或预防tau病的药物。本发明涉及一种治疗和/或预防tau病的药物，其包括Nav激活剂作为活性成分。
• PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT
  申请人：Mitsui Chemicals Agro, Inc.

  公开号：EP3611166A1

  公开（公告）日：2020-02-19

  This is to provide a novel compound capable of controlling plants diseases. The pyridone compound of the present invention is a novel compound and can control plants diseases.

  这是为了提供一种能够防治植物病害的新型化合物。本发明的吡啶酮化合物是一种新型化合物，可以防治植物病害。
• 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS
  申请人：SANOFI

  公开号：EP3416962B1

  公开（公告）日：2021-05-05
• BRIDGED BICYCLIC KALLIKREIN INHIBITORS
  申请人：GLOBAL BLOOD THERAPEUTICS, INC.

  公开号：US20160362427A1

  公开（公告）日：2016-12-15

  Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.
• NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF
  申请人：Sanofi

  公开号：US20170233340A1

  公开（公告）日：2017-08-17

  Compounds of formula (I): wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a —COOH, a —OH or a —OPO(OH) 2 group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a —OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a —COOH, —OH or —OPO(OH) 2 group, then R5 represents a hydrogen atom; when R5 represents a —OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group; and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.